title: Type 1 neurofibromatosis (von Recklinghausen disease).
abstract: Type 1 neurofibromatosis (NF1), or von  Recklinghausen disease, is a genetic disorder that is well known for its clinical features.  Effective treatment modalities for NF1 have not yet been established. The advent of new treatment options for NF1 such as topical vitamin D3 analogues, lovastatin, rapamycin (or sirolimus), and imatinib mesylate has added new dimensions that require further investigation to provide the greatest benefit to patients.
authors.affiliation: Dermato-Venerology Centre, Seghal Nursing Home, A/6 Panchwati, Delhi 220 033, India. drseghal@ndf.vsnl.net.in.
authors.forename: Virendra N
authors.initials: VN
authors.lastname: Sehgal
authors.forename: Prashant
authors.initials: P
authors.lastname: Verma
authors.forename: Kingsukh
authors.initials: K
authors.lastname: Chatterjee
mesh_terms: D000818:Animals; D002762:Cholecalciferol / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use; D008148:Lovastatin / Q000627:therapeutic use; D009456:Neurofibromatosis 1 / Q000188:drug therapy* / Q000235:genetics; D020123:Sirolimus / Q000627:therapeutic use
chemical_list: D002762:Cholecalciferol; D000068877:Imatinib Mesylate; D008148:Lovastatin; D020123:Sirolimus